rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1

by Montefiori DC, Huang Y, Karuna S, Allen M, Kochar N, Chappuis S, Gaillard J, Tomaras G, Graham B, Bart P, Pantaleo G
Published 2012-09-01

First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine

by Fuchs JD, Frank I, Kochar N, Elizaga M, Allen M, Carter D, Frahm N, Kalams SA, Mulligan M, Sheets R, Pensiero M, Clarke D, Eldridge J
Published 2012-09-01

P16-19. Statistical design and analysis of the CAVD-VIMC Elispot transfer study 001

by Bailer R, Cox J, Koup R, Self S, Levine G, Wan H, Sambor A, Tarragona T, Kochar N, Gill D, Wood B, Sato A, Huang Y, Gilmour J
Published 2009-10-01

DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies

by Fuchs JD, Morgan C, Bart P, Kochar N, Frahm N, Swann E, Gilbert P, DeRosa S, Graham B, Nabel G, Liao H, Haynes B, Tomaras G
Published 2012-09-01